INVESTIGATION OF MODIFIED SORAFENIB DERIVATIVES AS A TYROSINE KINASE INHIBITORS OF LEUKIMIA VIA MOLECULAR DOCKING. FMHR. 2026;4(5):567-585. Accessed May 21, 2026. https://fmhr.net/index.php/fmhr/article/view/2904